Empirical Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Empirical Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-407	Closed	-$392K	–	379
2024 Q1	$392K	Buy	407 +61	+18%	+$58K	0.19%	154
2023 Q4	$304K	Sell	346 -749	-68%	-$617K	0.25%	134
2023 Q3	$901K	Buy	1,095 +110	+11%	+$86.5K	0.79%	33
2023 Q2	$708K	Buy	985 +55	+6%	+$42.4K	0.63%	53
2023 Q1	$764K	Buy	930 +237	+34%	+$179K	0.73%	46
2022 Q4	$500K	Sell	693 -339	-33%	-$250K	0.53%	76
2022 Q3	$711K	Buy	1,032 +348	+51%	+$219K	0.78%	38
2022 Q2	$404K	Buy	+684	New	+$445K	0.43%	84

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Empirical Asset Management's REGN Position: Q2 2024 in Review

Empirical Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 407 shares — an estimated $392K sold.

Empirical Asset Management first reported a position in REGN in Q2 2022 and held it in 8 quarters. The position peaked at $901K in Q3 2023. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

Empirical Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Empirical Asset Management sold 407 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $392K.
Empirical Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2022 and held it in 8 quarters.
Empirical Asset Management's Regeneron Pharmaceuticals position peaked at $901K in Q3 2023.
1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Empirical Asset Management's 13F filing for Q2 2024, filed 12 Aug 2024.